AEON AEON BIOPHARMA INC revenue, earnings and financials
For the quarter ended June 30, 2026, AEON BIOPHARMA INC reported revenue of n/a, net income of −$1.16M and diluted EPS of −$0.02; for the fiscal year ended December 2025 revenue was n/a.
AEON annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$12.8M, net income −$39.2M (margin n/a), EPS −$3.95
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income $73.0M, net income $42.0M (margin n/a), EPS $72.93
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$48.4M, net income −$52.6M (margin n/a), EPS −$0.38
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$1.94M, net income $8.20M (margin n/a), EPS n/a
AEON quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$1.16M, EPS −$0.02
- Quarter ended Mar 31, 2026: revenue n/a, net income −$11.8M, EPS −$0.29
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$37.1M, EPS −$5.24
- Quarter ended Sep 30, 2025: revenue n/a, net income −$4.54M, EPS −$0.39
- Quarter ended Jun 30, 2025: revenue n/a, net income −$6.64M, EPS −$0.60
- Quarter ended Mar 31, 2025: revenue n/a, net income $9.10M, EPS $2.28
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income $2.08M, EPS $8.04
- Quarter ended Sep 30, 2024: revenue n/a, net income −$6.17M, EPS −$11.24
- Quarter ended Jun 30, 2024: revenue n/a, net income $164M, EPS $304.00
- Quarter ended Mar 31, 2024: revenue n/a, net income −$118M, EPS −$227.87
- Quarter ended Sep 30, 2023: revenue n/a, net income −$298M, EPS −$8.01
- Quarter ended Jun 30, 2023: revenue n/a, net income −$15.4M, EPS −$0.11
- Quarter ended Mar 31, 2023: revenue n/a, net income −$17.6M, EPS −$0.13
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$46.8M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$10.4M, EPS −$0.08
- Quarter ended Jun 30, 2022: revenue n/a, net income $1.87M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income $2.77M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income $248K, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income $5.66M, EPS n/a
- Quarter ended Jun 30, 2021: revenue n/a, net income −$4.03M, EPS n/a
AEON cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$17.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$20.3M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$35.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$1.49M, share buybacks n/a
AEON balance sheet
- Jun 30, 2026: cash $3.43M, total assets $5.91M, total liabilities $21.3M, shareholders' equity −$15.4M
- Mar 31, 2026: cash $6.24M, total assets $8.63M, total liabilities $25.4M, shareholders' equity −$16.8M
- Dec 31, 2025: cash $3.01M, total assets $5.56M, total liabilities $60.6M, shareholders' equity −$55.0M
- Sep 30, 2025: cash $5.93M, total assets $8.73M, total liabilities $28.6M, shareholders' equity −$19.9M
- Jun 30, 2025: cash $8.44M, total assets $11.7M, total liabilities $27.5M, shareholders' equity −$15.9M
- Mar 31, 2025: cash $10.4M, total assets $13.8M, total liabilities $25.1M, shareholders' equity −$11.3M
- Dec 31, 2024: cash $13.0K, total assets $3.14M, total liabilities $31.7M, shareholders' equity −$28.6M
- Sep 30, 2024: cash $537K, total assets $4.00M, total liabilities $36.1M, shareholders' equity −$32.1M
Is AEON profitable?
No. AEON BIOPHARMA INC lost $54.6M over the last four quarters.
What is AEON's EPS?
Diluted earnings per share over the last four quarters were −$5.94; −$0.02 in the latest quarter.